The findings revealed significant differences in acyl-carnitine levels between the two groups, suggesting disruptions in bioenergetic pathways among those with schizophrenia
Evaluating Long-Term Safety and Understanding Possible Side Effects Safety is one of the most common concerns patients bring up when considering GLP-1 medications
Anastasi, E., Scaramuzzino, S., Viscardi, M
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
However, pulmonary embolisms didnt increase at this rate
Remaining Challenges in ePA for GLP-1s While ePA greatly reduces friction, some challenges remain: Incomplete Payer Connectivity: Not every insurer will accept ePA for every drug/plan